Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma – Pivotal Phase III SUNMO study demonstrated an 11.5 ...

Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...

Lunsumio can cause serious and life-threatening neurological problems. Your healthcare provider will check you for neurologic problems during treatment with Lunsumio.

“Lunsumio and Polivy represent the first combination of a bispecific antibody and antibody-drug conjugate, which could avoid chemotherapy and potentially provide an alternative option for some ...

The National Comprehensive Cancer Network® (NCCN®) has recently added Lunsumio and Polivy to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A recommendation for ...

Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. This dual-targeting activates and ...